EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial

Felix Müller, Hannes Zaczek, Anna M Becker, Laura Ley, Stefan Borgwardt, Joyce Santos de Jesus, Nico Loh, Jan Kohut, Mathias Auernig, Christopher Boehlke, Matthias E Liechti

Med · 2025-09 · 6 (9) · 100725

DOI: 10.1016/j.medj.2025.100725 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Med, 2025-09. Verfasst von Felix Müller und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of Basel, Department of Psychiatry (UPK), 4012 Basel, Switzerland; University Hospital Basel and University of Basel, Division of Clinical…. Hauptthemen laut MEDLINE: Major Depressive Disorder, Lysergic Acid Diethylamide, Psychotherapy, Hallucinogens. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: This trial aimed to assess the efficacy of lysergic acid diethylamide (LSD)-assisted therapy in patients with moderate-to-severe major depressive disorder. METHODS: This was a randomized, parallel, double-blind, low-dose controlled trial (Clinicaltrials.gov: NCT03866252). Patients were randomly assigned in a 1:1 ratio to receive supportive psychotherapy and either 100 μg + 200 μg LSD or 25 μg + 25 μg LSD in two dosing sessions. The primary endpoints were the changes in scores on the Inventory of Depressive Symptomatology, in the Clinician-Rated (IDS-C) version (assessed by the treating therapist) and the Self-Rated (IDS-SR) version, from baseline to 2 weeks after the second administration. The IDS scores were also assessed 6 and 12 weeks after the second administration. FINDINGS: Thirty-one patients were randomized to the low-dose group, and 30 were randomized to the high-dose group. At the primary endpoint, least-squares mean change (LSM) in IDS-SR scores was -3.9 in the low-dose and -11.8 in the high-dose group (difference: -7.9; 95% CI, -16.0 to 0.3; effect size: -0.5; p = 0.059). LSM in IDS-C scores was -3.6 in the low-dose and -12.9 in the high-dose group (difference: -9.2; CI, -17.1 to -1.3; effect size: -0.6; p = 0.023; corrected

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderLysergic Acid DiethylamidePsychotherapyHallucinogensHumansMaleFemaleDouble-Blind MethodMiddle AgedAdultTreatment OutcomeDose-Response Relationship, DrugPsychiatric Status Rating Scales

Stichwörter der Autor:innen

LSDTranslation to patientsclinical trialdepressionhallucinogenspsychedelic-assisted therapypsychedelics

Substanzen

Lysergic Acid DiethylamideHallucinogens

Autor:innen und Institutionen

  • University of Basel, Department of Psychiatry (UPK), 4012 Basel, Switzerland; University Hospital Basel and University of Basel, Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department…
  • University of Basel, Department of Psychiatry (UPK), 4012 Basel, Switzerland.
  • University Hospital Basel and University of Basel, Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, 4031 Basel, Switzerland.
  • Department of Psychiatry and Psychotherapy, University of Lübeck, 23538 Lübeck, Germany.
  • University of Basel, Department of Psychiatry (UPK), 4012 Basel, Switzerland; University Hospital Basel, Department of Palliative Care, 4031 Basel, Switzerland.

Zitieren

APA

Müller, F., Zaczek, H., Becker, A. M., Ley, L., Borgwardt, S., Santos de Jesus, J., Loh, N., Kohut, J., Auernig, M., Boehlke, C., & Liechti, M. E. (2025). Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial. Med, 6(9), 100725. https://doi.org/10.1016/j.medj.2025.100725

Vancouver

Müller F, Zaczek H, Becker AM, Ley L, Borgwardt S, Santos de Jesus J, et al. Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial. Med. 2025;6(9):100725. doi:10.1016/j.medj.2025.100725

BibTeX
@article{Mller2025,
  author = {Müller, Felix and Zaczek, Hannes and Becker, Anna M and Ley, Laura and Borgwardt, Stefan and Santos de Jesus, Joyce and Loh, Nico and Kohut, Jan and Auernig, Mathias and Boehlke, Christopher and Liechti, Matthias E},
  title = {Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial},
  journal = {Med},
  year = {2025},
  volume = {6},
  number = {9},
  pages = {100725},
  doi = {10.1016/j.medj.2025.100725}
}
Kostenlos starten →